Published in J Soc Integr Oncol on January 01, 2010
A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality. Cancer Causes Control (2015) 1.11
Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial. PLoS One (2013) 0.80
Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells. Cancer Prev Res (Phila) (2015) 0.77
Phytoestrogens and risk of prostate cancer: a meta-analysis of observational studies. World J Surg Oncol (2015) 0.76
Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival. Cancer Med (2013) 0.76
Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research. Cancer Causes Control (2013) 0.75
Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2. Cancer Sci (2016) 0.75
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer (1991) 3.14
Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr (2001) 2.97
Isoflavonoid levels in spot urine are associated with frequency of dietary soy intake in a population-based sample of middle-aged and older Chinese in Singapore. Cancer Epidemiol Biomarkers Prev (1998) 1.99
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev (2006) 1.97
Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr (1991) 1.83
Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr (2002) 1.60
Effect of genistein on in vitro and in vivo models of cancer. J Nutr (1995) 1.56
Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev (2005) 1.55
Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am (2006) 1.40
Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res (2005) 1.40
Dietary soy intake and urinary isoflavone excretion among women from a multiethnic population. Cancer Epidemiol Biomarkers Prev (1998) 1.34
Prostate cancer detection at low prostate specific antigen. J Urol (2000) 1.34
Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. Nutr Cancer (1999) 1.32
Soy isoflavones in the treatment of prostate cancer. Nutr Cancer (2003) 1.24
Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate (1997) 1.23
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol (2003) 1.21
The specific role of isoflavones in reducing prostate cancer risk. Prostate (2004) 1.16
Estrogens and mechanisms of prostate cancer progression. Ann N Y Acad Sci (2006) 1.11
Dietary phytoestrogens and cancer: in vitro and in vivo studies. J Steroid Biochem Mol Biol (1992) 1.10
Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol (2006) 1.06
Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer (2004) 1.06
The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol (2005) 1.05
Chemoprevention of prostate cancer: concepts and strategies. Eur Urol (1999) 1.04
Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable, and fruit intake. Cancer Epidemiol Biomarkers Prev (1999) 1.01
Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology (2004) 1.00
A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer (2007) 0.99
Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology (2004) 0.99
Absorption and excretion of the soy isoflavone genistein in rats. J Nutr (1996) 0.99
Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol (2006) 0.97
Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst (2000) 0.96
Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol (2005) 0.96
Phytoestrogens and prostate disease. J Nutr (2000) 0.95
Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer (2005) 0.95
The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol (2001) 0.92
Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol (2007) 0.89
Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer (2007) 0.86
An automated patient registration and treatment randomization system. J Med Syst (1995) 0.82
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science (2004) 5.64
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell (2010) 4.32
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011) 4.30
Relative and absolute quantification of postsynaptic density proteome isolated from rat forebrain and cerebellum. Mol Cell Proteomics (2006) 3.56
Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol (2012) 3.51
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 3.25
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Intern Med (2011) 3.11
Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2009) 2.91
Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab (2008) 2.90
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet (2011) 2.85
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res (2009) 2.79
Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood (2009) 2.79
Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab (2010) 2.70
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care (2007) 2.67
Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. Nat Cell Biol (2011) 2.65
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate (2010) 2.40
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res (2007) 2.35
Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med (2008) 2.29
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2006) 2.15
The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem (2008) 2.09
Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J Cell Biol (2007) 2.07
Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res (2008) 1.99
Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell (2008) 1.94
Enhanced 2,3-butanediol production by Klebsiella pneumoniae SDM. Appl Microbiol Biotechnol (2008) 1.92
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.87
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care (2007) 1.87
Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology (2008) 1.83
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res (2008) 1.78
Ogg1 knockout-associated lung tumorigenesis and its suppression by Mth1 gene disruption. Cancer Res (2003) 1.75
Acetoin metabolism in bacteria. Crit Rev Microbiol (2007) 1.73
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med (2013) 1.69
Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2008) 1.67
Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer (2005) 1.65
Structure dissection of human progranulin identifies well-folded granulin/epithelin modules with unique functional activities. Protein Sci (2008) 1.60
Use of SNOMED CT to represent clinical research data: a semantic characterization of data items on case report forms in vasculitis research. J Am Med Inform Assoc (2006) 1.57
Quantum teleportation and entanglement distribution over 100-kilometre free-space channels. Nature (2012) 1.56
Selection of patients for clinical trials: an interactive web-based system. Artif Intell Med (2004) 1.55
Comparing heterogeneous SNOMED CT coding of clinical research concepts by examining normalized expressions. J Biomed Inform (2008) 1.53
Activated expression of an Arabidopsis HD-START protein confers drought tolerance with improved root system and reduced stomatal density. Plant Cell (2008) 1.53
Adhesion molecule-dependent mechanisms regulate the rate of macrophage clearance during the resolution of peritoneal inflammation. J Exp Med (2002) 1.51
Racial ethnic differences in rates and determinants of deceased donor kidney transplantation. J Am Soc Nephrol (2011) 1.48
Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease. J Biol Chem (2011) 1.48
Systematic approach for validating the ubiquitinated proteome. Anal Chem (2008) 1.47
Non-sterilized fermentative production of polymer-grade L-lactic acid by a newly isolated thermophilic strain Bacillus sp. 2-6. PLoS One (2009) 1.46
Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev (2006) 1.45
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care (2012) 1.45
Methods, quality control and specimen management in an international multicentre investigation of type 1 diabetes: TEDDY. Diabetes Metab Res Rev (2013) 1.43
Physicochemical properties of cross-linked poly-gamma-glutamic acid and its flocculating activity against kaolin suspension. J Biosci Bioeng (2005) 1.43
Polyubiquitination of prolactin receptor stimulates its internalization, postinternalization sorting, and degradation via the lysosomal pathway. Mol Cell Biol (2008) 1.41
TEDDY--The Environmental Determinants of Diabetes in the Young: an observational clinical trial. Ann N Y Acad Sci (2006) 1.40
The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26 s proteasome. J Biol Chem (2009) 1.39
Efficient internalization of MHC I requires lysine-11 and lysine-63 mixed linkage polyubiquitin chains. Traffic (2009) 1.39
Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev (2011) 1.38
A novel gene, encoding 6-hydroxy-3-succinoylpyridine hydroxylase, involved in nicotine degradation by Pseudomonas putida strain S16. Appl Environ Microbiol (2008) 1.38
A randomized controlled trial to increase cancer screening among attendees of community health centers. Ann Fam Med (2004) 1.37
Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. Mol Cell (2011) 1.37
Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med (2010) 1.34
Georgenia ruanii sp. nov., a novel actinobacterium isolated from forest soil in Yunnan (China), and emended description of the genus Georgenia. Int J Syst Evol Microbiol (2007) 1.34
Characterization of environmentally friendly nicotine degradation by Pseudomonas putida biotype A strain S16. Microbiology (2007) 1.34
Novel nicotine oxidoreductase-encoding gene involved in nicotine degradation by Pseudomonas putida strain S16. Appl Environ Microbiol (2008) 1.33
Production of 2,3-butanediol from corncob molasses, a waste by-product in xylitol production. Appl Microbiol Biotechnol (2010) 1.31
A novel whole-cell biocatalyst with NAD+ regeneration for production of chiral chemicals. PLoS One (2010) 1.31
Biotechnological routes based on lactic acid production from biomass. Biotechnol Adv (2011) 1.31
β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest (2015) 1.31
A novel NADH-dependent and FAD-containing hydroxylase is crucial for nicotine degradation by Pseudomonas putida. J Biol Chem (2011) 1.30
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther (2010) 1.30
Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care (2011) 1.30
Membrane-bound L- and D-lactate dehydrogenase activities of a newly isolated Pseudomonas stutzeri strain. Appl Microbiol Biotechnol (2007) 1.27
B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care (2013) 1.25
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care (2013) 1.23
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol (2013) 1.23
Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care (2007) 1.22
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care (2013) 1.21
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol (2003) 1.21
Heterogeneous but "standard" coding systems for adverse events: Issues in achieving interoperability between apples and oranges. Contemp Clin Trials (2008) 1.21
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res (2009) 1.20
Systematic unraveling of the unsolved pathway of nicotine degradation in Pseudomonas. PLoS Genet (2013) 1.19
Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care (2011) 1.19
Congenital short pancreas. Chin Med J (Engl) (2007) 1.18
Relation of family history of prostate cancer to perceived vulnerability and screening behavior. Psychooncology (2004) 1.17
Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res (2007) 1.16
The specific role of isoflavones in reducing prostate cancer risk. Prostate (2004) 1.16
Genomic analysis of Pseudomonas putida: genes in a genome island are crucial for nicotine degradation. Sci Rep (2012) 1.15
Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis (2013) 1.15
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res (2011) 1.15